Type 2 diabetes mellitus
Conditions
Interventions
None listed
Sponsors
Teijin Pharma Limited
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with type 2 diabetes who were prescribed DPP-4 inhibitors during the enrollment period (December 2016 - February 2019) 2. Patients who were prescribed DPP-4 inhibitor monotherapy on an outpatient basis from a single institution under the definition of type 2 diabetes on the index date (the date when prescription of DPP-4 inhibitors was started during the enrollment period) 3. Patients who had been consecutively registered in the database for at least 1 year before the index date (baseline period) 4. Patients who have been consecutively registered in the database for 1 year after the index date (follow-up period) 5. Patients over the age of 18 in the index month
Exclusion criteria
Exclusion criteria: 1. Patients who were designated as having type 1 diabetes during the baseline period 2. Patients who had been prescribed DPP-4 inhibitors (single drug or combination drug) during the baseline period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Medication persistence (the duration of time from initiation to discontinuation of therapy, the probability of medication persistence) 2. Medication adherence | — |
Secondary
| Measure | Time frame |
|---|---|
| Glycemic control | — |
Countries
Japan
Contacts
Public ContactTetsuya Miwa
Teijin Pharma Limited Medical Science Department
Outcome results
None listed